0001104659-24-034670.txt : 20240314
0001104659-24-034670.hdr.sgml : 20240314
20240314205123
ACCESSION NUMBER: 0001104659-24-034670
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240313
FILED AS OF DATE: 20240314
DATE AS OF CHANGE: 20240314
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gilad Oren
CENTRAL INDEX KEY: 0001929300
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39069
FILM NUMBER: 24752206
MAIL ADDRESS:
STREET 1: 535 BOYLSTON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aprea Therapeutics, Inc.
CENTRAL INDEX KEY: 0001781983
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3805 OLD EASTON ROAD
CITY: DOYLESTOWN
STATE: PA
ZIP: 18902
BUSINESS PHONE: 617-463-9385
MAIL ADDRESS:
STREET 1: 3805 OLD EASTON ROAD
CITY: DOYLESTOWN
STATE: PA
ZIP: 18902
4
1
tm248935-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-03-13
0
0001781983
Aprea Therapeutics, Inc.
APRE
0001929300
Gilad Oren
3805 OLD EASTON ROAD
DOYLESTOWN
PA
18902
1
1
0
0
President, CEO
0
Common Stock
2024-03-13
4
P
0
2000
7.29
A
324770
D
Tranche A Warrant
2024-03-13
4
P
0
1000
A
2024-03-13
Common Stock
1000
1000
D
Tranche B Warrant
2024-03-13
4
P
0
1000
A
2024-03-13
Common Stock
1000
1000
D
The exercise price of the Tranche A Warrants is as follows: 1,000 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share.
Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.
The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.
The exercise price of the Tranche B Warrants is as follows: 1,000 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share.
Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.
The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.
/s/ John Hamill, as Attorney-in-Fact
2024-03-14